Evidence map›Paper›PMID 31664910›Full record

ArticleBMC infectious diseases2019

Self-reported antiretroviral therapy adherence and viral load in criminal justice-involved populations.

William E Cunningham, Robin M Nance, Carol E Golin, Patrick Flynn, Kevin Knight, Curt G Beckwith, Irene Kuo, Anne Spaulding, Faye S Taxman, Fredrick Altice and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC infectious diseases, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

William E CunninghamDepartment of Medicine, Div GIM & HSR, Geffen School of Medicine, UCLA, 911 Broxton Ave, Los Angeles, CA, 90024, USA. wcunningham@mednet.ucla.edu.ORCID http://orcid.org/0000-0002-9927-134X
Robin M NanceDepartment of Medicine, University of Washington, Seattle, WA, USA.
Carol E GolinDivision of General Medicine and Epidemiology, University of North Carolina at Chapel Hill School of Medicine, Gillings School of Global Public Health, 310 Rosenau Hall, CB #7440, Chapel Hill, NC, 27599, USA.
Patrick FlynnInstitute of Behavioral Research, Texas Christian University, TCU Box 298740, Fort Worth, TX, 76129, USA.
Kevin KnightInstitute of Behavioral Research, Texas Christian University, TCU Box 298740, Fort Worth, TX, 76129, USA.
Curt G BeckwithDepartment of Medicine, Alpert Medical School of Brown University and The Miriam Hospital, 1125 North Main St, Providence, RI, 02904, USA.
Irene KuoDepartment of Epidemiology and Biostatistics, George Washington University Milken Institute School of Public Health, 950 New Hampshire Ave, NW, 7th Floor, Washington, DC, 20052, USA.
Anne SpauldingRollins School of Public Health, Emory University, 1518 Clifton Road, Atlanta, GA, 30322, USA.
Faye S TaxmanDepartment of Criminology, Law & Society, George Mason University, 4087 University Drive 4100 MSN 6D3, Fairfax, VA, 22030, USA.
Fredrick AlticeSection of Infectious Diseases, AIDS Program, Yale University School of Medicine, 135 College Street, Suite 323, New Haven, CT, 06510-2283, USA.
Joseph A DelaneyDepartment of Epidemiology, University of Washington, Seattle, WA, USA.
Heidi M CraneFaculty of Medicine, University of Washington, Seattle, WA, USA.
Sandra A SpringerDepartment of Internal Medicine, Section of Infectious Disease, Yale AIDS Program, Yale New Haven Hospital, Yale University School of Medicine, 135 College street, Suite 323, 20 York Street, New Haven, CT, 06510, USA. sandra.springer@yale.edu.

Funding

UCLA Clinical Translational Science InstituteUL1TR001881 · NCATS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI ARLEEN F. BROWN, ARASH NAEIM · 2016 to 2026
$118.1M
University of Washington/Fred Hutch Center for AIDS ResearchP30AI027757 · NIAID · UNIVERSITY OF WASHINGTON · PI EDWIN ROBERTO ORELLANA · 1988 to 2026
$104.9M
Yale Clinical and Translational Science Award (U Component)UL1TR001863 · NCATS · YALE UNIVERSITY · PI John H. Krystal, LUCILA OHNO-MACHADO · 2016 to 2026
$102.9M
Virology, Immunology, and Microbiology CoreP30AI050410 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI DAVID M. MARGOLIS · 2001 to 2026
$76.9M
UCLA Rapid, Relevant, Rigorous Implementation Science HubP30MH058107 · NIMH · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Nina Thawata Harawa · 1997 to 2026
$53.5M
The Center for Health Improvement of Minority ElderlyP30AG021684 · NIA · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Homero Erwin del Pino · 2002 to 2026
$19.7M
RCT of an augmented test, treat, link, & retain model for NC and Texas prisonersR01DA030793 · NIDA · UNIV OF NORTH CAROLINA CHAPEL HILL · PI FLYNN, PATRICK M, GOLIN, CAROL E · 2010 to 2015
$6.9M
CARE Corrections: Technology for Jail HIV/HCV Testing, Linkage, and Care (TLC)R01DA030747 · NIDA · MIRIAM HOSPITAL · PI BECKWITH, CURT G, KUO, IRENE · 2010 to 2014
$4.9M
Effectiveness of Peer Navigation to Link Released HIV+ Jail Inmates to HIV CareR01DA030781 · NIDA · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI CUNNINGHAM, WILLIAM EMERY · 2010 to 2015
$4.5M
Naltrexone for Opioid Dependent Released HIV+ Criminal Justice PopulationsR01DA030762 · NIDA · YALE UNIVERSITY · PI SPRINGER, SANDRA ANN · 2010 to 2015
$4.1M
HIV, Buprenorphine, and the Criminal Justice SystemR01DA030768 · NIDA · YALE UNIVERSITY · PI ALTICE, FREDERICK LEWIS · 2010 to 2015
$4.0M
Seek, Test, Treat, and Retain Data Harmonization Coordinating CenterU01DA037702 · NIDA · UNIVERSITY OF WASHINGTON · PI CRANE, HEIDI M., DELANEY, JOSEPH AUSTIN · 2014 to 2019
$3.8M
Center for Clinical and Translational Science, University of Los Angeles UL1-TR001881National Institute on Drug Abuse (US) R01-DA030747NCATS NIH HHS UL1 TR001863NCATS NIH HHS UL1 TR001881NIAID NIH HHS P30 AI027757NIAID NIH HHS P30 AI050410NIA NIH HHS P30 AG021684NIA NIH HHS P30-AG021684NIDA NIH HHS 5U01-DA037702NIDA NIH HHS K02 DA032322NIDA NIH HHS K02DA032322NIDA NIH HHS R01 DA030747NIDA NIH HHS R01-DA030747NIDA NIH HHS R01 DA030762NIDA NIH HHS R01-DA030762NIDA NIH HHS R01 DA030768NIDA NIH HHS R01 DA030781NIDA NIH HHS R01-DA030781NIDA NIH HHS R01 DA030793NIDA NIH HHS R01DA030793NIDA NIH HHS R01 DA039934NIDA NIH HHS R01-DA039934NIDA NIH HHS R34 DA035728NIDA NIH HHS R34-DA035728-01A1NIDA NIH HHS ROI DA030768NIDA NIH HHS U01 DA037702NIMH NIH HHS P30 MH058107NIMH NIH HHS P30-MH58107NIMH NIH HHS R01 MH103076NIMH NIH HHS R01-MH103076NINR NIH HHS R01 NR017334NINR NIH HHS R01-NR017334NINR NIH HHS R01-NR4014789
6 · The paper itself

Abstract

backgroundSelf-reported antiretroviral therapy (ART) adherence measures that are associated with plasma viral load (VL) are valuable to clinicians and researchers, but are rarely examined among groups vulnerable to dropping out of care. One-seventh of all those living with HIV pass through incarceration annually and criminal-justice (CJ) involved people living with HIV (PLH) are vulnerable to falling out of care. We examined the association of self-reported ART adherence with VL in a criminal-justice sample compared to a routine-care sample.

methodsSamples: We examined data from a multisite collaboration of studies addressing the continuum of HIV care among CjJ involved persons in the Seek, Test, Treat, and Retain cohort. Data pooled from seven CJ- studies (n = 414) were examined and compared with the routine-care sample from the Centers for AIDS Research Network of Integrated Clinical Systems' seven sites (n = 11,698). MEASURES: In both samples, data on self-reported percent ART doses taken were collected via the visual analogue scale adherence measure. Viral load data were obtained by blood-draw. ANALYSIS: We examined the associations of adherence with VL in both cohorts using mixed effects linear regression of log-VL, and mixed effects logistic regression of binary VL (≥ 200 copies/mL) outcomes. Interactions by CD4 count and self-reported health status were also tested.

resultsAmong the CJ sample, the coefficient for log-VL was - 0.31 (95% CI = - 0.43, - 0.18; P < 0.01) and that in the routine-care sample was - 0.42 (95% CI = - 0.45, - 0.38; P < 0.01). For the logistic regression of binary detectable VL on 10% increments of adherence we found the coefficient was - 0.26 (95% CI = - 0.37, - 0.14; P < 0.01) and in the routine-care sample it was - 0.38 (95% CI = - 0.41, - 0.35; P < 0.01). There was no significant interaction by CD4 count level in the CJ sample, but there was in the routine-care sample. Conversely, there was a significant interaction by self-reported health status level in the criminal-justice sample, but not in the routine-care sample.

conclusionsThe visual analogue scale is valid and useful to measure ART adherence, supporting treatment for CJ- involved PLH vulnerable to falling out of care. Research should examine adherence and VL in additional populations.

Indexed as

Antiretroviral Therapy, Highly ActiveCriminalsMedication AdherenceSelf ReportViral LoadAdultAnti-Retroviral AgentsCD4 Lymphocyte CountCohort StudiesCriminal LawFemaleHealth StatusHIVHIV InfectionsHumansLogistic ModelsAnti-Retroviral AgentsAntiretroviral therapyCriminal justice-involved populations (5 key words)IncarcerationMedication adherenceViral load

Identifiers

PMID31664910
PMCPMC6819597

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.